Understanding and meeting injection device needs in multiple sclerosis: A survey of patient attitudes and practices

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 173-180

  di Cantogno, Elisabetta Verdun ^a   Russell, Susan ^a   Snow, Tom ^a  

^a MERCK SERONO S A   (Switzerland)

Author keywords

Adherence; Autoinjection; Multiple sclerosis; Subcutaneous interferon beta 1a

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; AGED; CLINICAL PRACTICE; ELECTRONICS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; MULTIPLE SCLEROSIS; NEEDLE; ONLINE SYSTEM; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT PREFERENCE; PATIENT SATISFACTION; PHOBIA; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; REVIEW; SELF INJECTION; TREATMENT OUTCOME;

EID: 80054898365     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S14903     Document Type: Review

References (15)

1. Ford HL, Gerry E, Johnson M, Williams R. A prospective study of the incidence, prevalence and mortality of multiple sclerosis in Leeds. J Neurol. 2002;249:260-265.
2. Sloka JS, Pryse-Phillips WE, Stefanelli M. Incidence and prevalence of multiple sclerosis in Newfoundland and Labrador. Can J Neurol Sci. 2005;32:37-42.
3. Inglese M. Multiple sclerosis: New insights and trends. Am J Neuroradiol. 2006;27:954-957.
4. Al-Sabbagh A, Bennet R, Kozma C, Dickson M, Meletiche D. Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: Findings from a national managed care database. J Neurol. 2008;255 Suppl 2:S79.
5. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10:225.
6. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2010 Jun 14. [Epub ahead of print].
7. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256: 568-576.
8. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv. 2009;6:995-1002.
9. Brochet B, Lemaire G, Beddiaf A. Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices. Rev Neurol (Paris). 2006;162: 735-740. French.
10. Lugaresi A, Durastanti V, Gasperini C, et al. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: The CoSa study. Clin Neuropharmacol. 2008;31:167-172.
11. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11:585-591.
12. Bayas A, Japp G, Fulda U, Kallmann B. Injection devices in the basic therapy of multiple sclerosis. Survey among neurologists, MS nurses and patients. Nervenheilkunde. 2010;29:57-62. [German].
13. Devonshire V, Arbizu T, Borre B, et al. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: An international, single-arm, multicentre, Phase IIIb study. BMC Neurol. 2010;10:28.
14. Exell S, Verdun E, Driebergen R, Migliaccio M. Development of an electronic injection device for subcutaneous interferon beta-1a administration in patients with relapsing multiple sclerosis. J Neurol Sci. 2009;285 Suppl:S203.
15. Diglas J, Feinbock C, Irsigler K, et al. Reduced pain perception with Pen Mate™, an automatic needle insertion device for use with an insulin pen. Practical Diabetes. 1999;16:39-41.